- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02971878
Comparisons of Human Embryonic Development Using Single Medium With and Without the Addition of Antioxidants
Adding Antioxidants Into Human Embryo Culture Media
Aim: To investigate the impact of antioxidants (acetyl-L-carnitine, N-acetyl-L-cysteine and a-lipoic acid) on embryo development and subsequently the clinical outcome. Including clinics using low oxygen and ambient air during embryo culture. Analysed with time-lapse system.
Study media: G-TL with antioxidants. Control media: Same media without antioxidants. Type of study: Study comparing blastocyst development on the same cohort of oocytes using two different media, G-TL versus G-TL supplemented with antioxidants. Statistics based on an absolute increase in Good Quality Blastocysts on day 5 of 7%.
Design: Multicentre prospective randomized sibling trial. Single blastocyst transfer. Superiority study Primary Endpoint: Good Quality Blastocysts on day 5 per allocated normally fertilized oocyte.
Patients: Comparative embryo sibling study with 128 patients included.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study objective: Study comparing blastocyst development on the same cohort of oocytes using two different media, G-TL versus G-TL supplemented with antioxidants.
Primary endpoint: Percentage of good quality blastocysts (GQB) per fertilized oocyte on day 5.
Secondary endpoints
- Embryo development day 3, 5 and 6
- Embryo quality day 3, 5 and 6
- Total blastocyst formation (day 5 and day 6)
- Utilization rate (embryos available for transfer and cryopreservation)
- Implantation rate
- Clinical pregnancy rate
Setup: Prospective embryo sibling, superiority study
MATERIALS AND METHODS Intervention New type of embryo culture media used for in vitro culture of human IVF embryos.
Power analysis The planning and the power analysis was made together with a statistician, Nils-Gunnar Pehrsson.
From retrospective data using simulation, the intra individual SD for the difference in % GQB between the two media strategies was estimated to 32%. In order to find a difference in 8% in GQB between the two media with power 80% with paired T-test 128 couples will be needed.
Randomization Couples will be enrolled in the study after fertilization check (day 1). A minimum of 6 zygotes is required for participation.
Stratified randomization of the zygotes by couple will be performed. For each couple the zygotes will be numbered.
These zygotes for each couple will then be block (by two) randomized to the two media types; A (Traditional culture media = Control) and B (Antioxidant media = intervention). In both groups traditional culture will be performed. Allocation will be performed in a 1:1 ratio according to a unique randomization list for each couple.
Blinding To minimize possible bias for the primary outcome (GQE D5) the embryologist performing the morphological evaluation on day 5/6 will not know which group the embryos belong to.
Both the physician and the couple will be blinded to which group they have been allocated.
IVF treatment procedure A traditional IVF treatment will be performed including ovarian stimulation and oocyte pick-up using the standard methods at the clinics.
Embryo assessment and timing of assessment according to Alpha/ESHRE consensus criteria.
Morphological scoring Blastocyst morphology will be scored according to Consensus Scoring system for blastocysts (Istanbul Consensus workshop on embryo assessment) and the morphology will be documented with individual photos of each blastocyst. Blastocyst scoring will be performed under an inverted microscope on day 5 and day 6. A good quality blastocyst is defined as at least Grade 2:2:2 according to Istanbul Consensus grading system. (Balaban et al., 2011).
DOCUMENTATION All patients participating in the study will be documented on a computerized CRF. This document will be related to patients' records with all relevant clinical and laboratory data from the specific IVF cycle. Through the journal system (WinIVF) used at Fertilitetscentrum, it will be possible to generate a complete list of all the variables included in the study.
Patients who have been asked to participate in the study but did not fulfill the criteria for randomization will also be registered.
STATISTICAL ANALYSIS Both an Intention-to-Treat (ITT) population and a Per Protocol (PP) population will be defined. Primary efficacy variable in this superiority study will be difference in %GQB between the two media types for each couple. Primary statistical analysis will be two-sided paired T-test regarding the mean of difference in %GQB between Standard culture media and Antioxidant media on the ITT population. A two sided 95% confidence interval for the mean difference in %GOB between the two media will be calculated. All significance tests will be two-sided and conducted at the 5% significance level.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Box 5418
-
Gothenburg, Box 5418, Sweden, 40229
- Fertilitetscentrum
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Couples with female, male or unexplained infertility intending to undergo IVF
- The couple should have received verbal and written information/consent about the study.
- 6 or more fertilized oocytes on day 1
- Blastocyst culture and transfer on day 5
- Signed written consent
Exclusion Criteria:
- Previous participation in the study.
- Testicular biopsy patients (TESA/TESE)
- Fewer than 6 fertilized oocytes.
- If split IVF is needed.
- Total freeze on day 3
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
No Intervention: Control
Culture media without addition of antioxidants
|
|
Active Comparator: Treatment
Culture media with the addition of antioxidants
|
Human embryos will be cultured in media that contains 3 antioxidants (Acetyl-L-carnitine (ALC), N-acetyl-L-cysteine (NAC) and α-lipoic acid (ALA)) that can be found in the in vivo Environment.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Percentage of good quality blastocysts (GQB) per randomized embryo
Time Frame: 7 months
|
7 months
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Total blastocyst rate
Time Frame: 7 months
|
7 months
|
Implantation rate
Time Frame: 8 months
|
8 months
|
Pregnancy rate
Time Frame: 10 months
|
10 months
|
Utilization rate
Time Frame: 7 months
|
7 months
|
Embryo development (Kinetics) day 3,5 & 6
Time Frame: 7 months
|
7 months
|
Embryo quality dag 3,5 and 6
Time Frame: 7 months
|
7 months
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Study Chair: Thorir Hardarson, PhD, Fertilitetscentrum AB
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Antiviral Agents
- Protective Agents
- Micronutrients
- Respiratory System Agents
- Vitamins
- Antioxidants
- Antidotes
- Vitamin B Complex
- Free Radical Scavengers
- Nootropic Agents
- Expectorants
- Acetylcysteine
- N-monoacetylcystine
- Acetylcarnitine
- Thioctic Acid
Other Study ID Numbers
- GTL-X
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Blastocyst
-
Instituto Valenciano de Infertilidad, IVI VALENCIACompleted
-
V.K.V. American Hospital, IstanbulCompleted
-
Ganin Fertility CenterCompletedBlastocyst | Implantation RateEgypt
-
VitrolifeCompletedBlastocyst | Human | Antioxidants | Oxygen | Culture Media | EmbryoJapan
-
IVI MadridTerminatedBlastocyst Time | Pronuclear Appearance | Pronuclear Fading | Embryo Compaction | Cleavage TimesSpain
-
Unità di Medicina della Riproduzione, ItalyCompletedIncrease the Number of Blastocyst to Biopsy for Preimplantation Genetic TestingItaly
-
Benha UniversityCompleted
-
European HospitalUnknownEmbryo Development | Blastocyst | Culture Media | Poor Responder | Severe Male InfertilityItaly
-
Benha UniversityHawaa Fertility CenterTerminatedBlastocyst DisintegrationEgypt
-
Bloom IVF and Fertility CentrePadmashree Dr. D. Y. Patil Medical CollegeUnknownAneuploidy | Blastocyst Disintegration | Embryo/Fetus Death | Complication of Implant | Chemical PregnancyIndia
Clinical Trials on Acetyl-L-carnitine (ALC), N-acetyl-L-cysteine (NAC) and α-lipoic acid (ALA)
-
VitrolifeCompletedBlastocyst | Human | Antioxidants | Oxygen | Culture Media | EmbryoJapan
-
Children's Hospital Medical Center, CincinnatiUnited States Department of DefenseRecruitingNeurofibromatosis 1United States
-
Vanderbilt UniversityCompleted
-
Wake Forest University Health SciencesNational Cancer Institute (NCI)WithdrawnHead and Neck Cancer
-
Children's Hospital Medical Center, CincinnatiActive, not recruitingNeurofibromatosis 1United States
-
Amen Clinics, Inc.CompletedTraumatic Brain InjuryUnited States
-
Karin HighUniversity of KentuckyTerminated
-
UPECLIN HC FM Botucatu UnespFundação de Amparo à Pesquisa do Estado de São PauloCompletedHIV Infection
-
Peking University People's HospitalActive, not recruitingStem Cell Transplant ComplicationsChina
-
Peking University People's HospitalNanfang Hospital of Southern Medical University; The First Affiliated Hospital...TerminatedThrombocytopenia | Stem Cell Transplant ComplicationsChina